Rules-Based Medicine Pulls IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine is pulling its initial public offering citing adverse market conditions.

In a document filed with the US Securities and Exchange Commission on Tuesday, the Austin, Texas-based multiplex molecular diagnostics firm said it plans to withdraw its IPO due to market conditions, but it did not elaborate further. A company spokesman also declined to comment further on the withdrawal of the IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.